Yuming Mm Yao

Yuming Mm Yao

Auto-generated profile, based on publicly available information

Yuming Mm Yao

Department of Orthopedics, Xiangya Hospital, Central South University, Changsha, Hunan, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 November 2024 in Medicine
Verified
Journal Article
Open access
YYYuming Mm Yao
Yuming Mm Yao
RZRuhao Zhou
Ruhao Zhou
GYGuang Yang
Guang Yang
BJBingzhou Mm Ji
Bingzhou Mm Ji
Yusheng LiYusheng Li
Yusheng Li
JZJun Zhang
Jun Zhang
Chondrosarcoma is 1 of the most common malignant bone tumors, with dedicated research being conducted by scientists worldwide. The purpose of this study was to guide researchers in identifying valuable scholars, institutions, and countries, provide recommendations for journal submissions, and explore research trends and hotspots in chondrosarcoma studies through literature analysis. Data for this study were collected from the Web of Science Core Collection website. The R package bibliometrix was utilized for citation metrics analysis, VOSviewer for network analysis, and CiteSpace for generating keywords citation burst maps. The analysis focused on publications from 2000 to 2023, identifying trends, authorship patterns, and collaboration networks. A total of 2085 articles were initially identified, but after excluding non-English articles and those outside the study’s time range, 2022 articles were included. The field comprised 9954 author records, with an average of 6.37 coauthors per document and 13.9% international co-authorships. Publications in chondrosarcoma research have shown an average annual growth rate of 3.9%. The most influential author identified was Tang Chih-Hsin from China Medical University. Significant contributions came from China Medical University and Leiden University, with China showing a dramatic increase in publications while the United States maintained a leading position in the field. The study highlights an increasing trend in chondrosarcoma research publications and identifies key contributors and institutions. Cancer emerged as 1 of the most influential journals in the field. Future research is likely to focus on targeted therapy for refractory chondrosarcomas, indicating a potential new hotspot in the ongoing efforts to understand and treat this malignancy.

30 May 2026 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
YYYuming Yao
Yuming Yao
GLGaoming Liu
Gaoming Liu
DVDjandan Tadum Arthur Vithran
Djandan Tadum Arthur Vithran
WXWenfeng Xiao
Wenfeng Xiao
Yusheng LiYusheng Li
Yusheng Li
This study aimed to clarify the latest epidemiologic trends, economic costs, and key drivers of musculoskeletal disorders (MSDs) in high-income regions, where the disease burden has increased despite high overall healthcare spending. Utilising data from the Global Burden of Disease 2023 database, we analysed the trends in incidence, prevalence, and years lived with disability (YLDs) for MSD across 36 high-income countries from 1990 to 2023. Bayesian meta-regression models were employed to quantify the burden attributable to major risk factors. A cross-national transfer model was used to estimate the direct healthcare economic costs associated with MSD in 2023. Spearman correlation analysis was applied to explore the relationship between the Sociodemographic Index (SDI) and disease burden, and trends in disease burden were forecasted for the period 2024 to 2050. Between 1990 and 2023, the total number of incident cases, prevalent cases, and YLDs for MSD in high-income regions increased by 36.75%, 54.28%, and 49.36%, respectively. Although the age-standardised incidence rate decreased by 4.07%, the standardised prevalence and YLD rates increased by 5.04% and 3.98%, respectively, indicating a continuously growing absolute disease burden. Low back pain and osteoarthritis accounted for the largest proportion of the disease burden. For all MSD subtypes except gout, the burden was higher in females than in males. In 2023, the direct medical costs associated with MSD reached as high as $327.68 billion, with the United States accounting for >45% of this amount. Regarding risk factors, the proportion of YLDs attributable to high body mass index increased from 8.3% in 1990 to 10.7% in 2023. The contribution of occupational ergonomic factors remained stable at approximately 7.7%, whereas the smoking-related burden decreased by 30%. Correlation analysis revealed no significant association between the SDI and the age-standardised burden rates of MSD. The burden of MSD in high-income regions continues to intensify, driven primarily by ageing, obesity, and occupational factors, and has not been alleviated by economic development. Future prevention and control efforts should focus on weight management and occupational ergonomic interventions to curb the growth of the disease and mitigate the substantial economic pressure.